{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:17:06Z","timestamp":1790925426665,"version":"4.1.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"am","delay-in-days":362,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA247619-01A1S1"],"award-info":[{"award-number":["R01 CA247619-01A1S1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.coviro.2022.101270","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T14:04:43Z","timestamp":1664373883000},"page":"101270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Druggable host\u00a0gene dependencies in primary\u00a0effusion lymphoma"],"prefix":"10.1016","volume":"56","author":[{"given":"Neil","family":"Kuehnle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gottwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2022.101270_bib1","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199505043321802","article-title":"Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas","volume":"332","author":"Cesarman","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coviro.2022.101270_bib2","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood.V88.2.645.bloodjournal882645","article-title":"Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus","volume":"88","author":"Nador","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101270_sbref3","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.2020005470","article-title":"KSHV\/HHV8-mediated hematologic diseases","volume":"139","author":"Cesarman","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101270_bib4","article-title":"Cancers associated with human gammaherpesviruses","author":"Wen","year":"2021","journal-title":"FEBS J"},{"key":"10.1016\/j.coviro.2022.101270_bib5","doi-asserted-by":"crossref","first-page":"8143","DOI":"10.1128\/JVI.72.10.8143-8149.1998","article-title":"Persistent infection of Epstein-Barr virus-positive B lymphocytes by human herpesvirus 8","volume":"72","author":"Kliche","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2022.101270_bib6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/blood-2003-05-1710","article-title":"Infection of HHV-8+ primary effusion lymphoma cells with a recombinant Epstein-Barr virus leads to restricted EBV latency, altered phenotype, and increased tumorigenicity without affecting TCL1 expression","volume":"103","author":"Trivedi","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101270_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.chom.2017.06.009","article-title":"Persistent KSHV infection increases EBV-Associated tumor formation in vivo via enhanced EBV lytic gene expression","volume":"22","author":"McHugh","year":"2017","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coviro.2022.101270_bib8","doi-asserted-by":"crossref","first-page":"16519","DOI":"10.1073\/pnas.1905025116","article-title":"How Kaposi's sarcoma-associated herpesvirus stably transforms peripheral B cells towards lymphomagenesis","volume":"116","author":"Faure","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2022.101270_bib9","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1182\/blood-2010-12-323659","article-title":"Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines","volume":"118","author":"Roy","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101270_bib10","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/path.2752","article-title":"Primary effusion lymphoma: genomic profiling revealed amplification of SELPLG and CORO1C encoding for proteins important for cell migration","volume":"222","author":"Luan","year":"2010","journal-title":"J Pathol"},{"key":"10.1016\/j.coviro.2022.101270_bib11","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1128\/JVI.01757-06","article-title":"Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy","volume":"81","author":"Petre","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2022.101270_bib12","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3324\/haematol.2009.007260","article-title":"Mutational analysis of TP53, PTEN, PIK3CA and CTNNB1\/beta-catenin genes in human herpesvirus 8-associated primary effusion lymphoma","volume":"94","author":"Boulanger","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.coviro.2022.101270_bib13","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/sj.onc.1205360","article-title":"p16INK4a loss and sensitivity in KSHV associated primary effusion lymphoma","volume":"21","author":"Platt","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.coviro.2022.101270_bib14","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2019-01-893339","article-title":"Viral, immunologic, and clinical features of primary effusion lymphoma","volume":"133","author":"Lurain","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101270_bib15","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1172\/JCI30945","article-title":"Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas","volume":"117","author":"Sarek","year":"2007","journal-title":"J Clin Investig"},{"key":"10.1016\/j.coviro.2022.101270_bib16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1128\/JVI.75.1.429-438.2001","article-title":"Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53","volume":"75","author":"Rivas","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2022.101270_bib17","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1182\/blood-2004-08-3052","article-title":"Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA","volume":"105","author":"Godfrey","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101270_bib18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1182\/blood-2007-05-092288","article-title":"The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells","volume":"111","author":"Wies","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101270_bib19","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1021\/acsnano.9b06333","article-title":"Specific Inhibition of viral microRNAs by carbon dots-mediated delivery of locked nucleic acids for therapy of virus-induced cancer","volume":"14","author":"Ju","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.coviro.2022.101270_bib20","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02045-16","article-title":"Kaposi's Sarcoma-associated herpesvirus microRNAs target GADD45B to protect infected cells from cell cycle arrest and apoptosis","volume":"91","author":"Liu","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2022.101270_bib21","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nature05992","article-title":"A viral microRNA functions as an orthologue of cellular miR-155","volume":"450","author":"Gottwein","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2022.101270_bib22","doi-asserted-by":"crossref","first-page":"12836","DOI":"10.1128\/JVI.01804-07","article-title":"Renne R: Kaposi's sarcoma-associated herpesvirus encodes an ortholog of miR-155","volume":"81","author":"Skalsky","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2022.101270_bib23","doi-asserted-by":"crossref","first-page":"9877","DOI":"10.1128\/JVI.05558-11","article-title":"A Kaposi's sarcoma-associated herpesvirus-encoded ortholog of microRNA miR-155 induces human splenic B-cell expansion in NOD\/LtSz-scid IL2Rgammanull mice","volume":"85","author":"Boss","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2022.101270_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049435","article-title":"A microRNA encoded by Kaposi Sarcoma-associated herpesvirus promotes B-cell expansion in vivo","volume":"7","author":"Dahlke","year":"2012","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.coviro.2022.101270_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01053-18","article-title":"In vivo models of oncoproteins encoded by Kaposi's Sarcoma-associated herpesvirus","volume":"93","author":"Bravo Cruz","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2022.101270_bib26","doi-asserted-by":"crossref","first-page":"E11379","DOI":"10.1073\/pnas.1810128115","article-title":"Epstein-Barr virus enhances genome maintenance of Kaposi sarcoma-associated herpesvirus","volume":"115","author":"Bigi","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2022.101270_bib27","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nmeth.3047","article-title":"Improved vectors and genome-wide libraries for CRISPR screening","volume":"11","author":"Sanjana","year":"2014","journal-title":"Nat Methods"},{"key":"10.1016\/j.coviro.2022.101270_bib28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1247005","article-title":"Genome-scale CRISPR-Cas9 knockout screening in human cells","volume":"343","author":"Shalem","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.coviro.2022.101270_bib29","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1126\/science.aac7041","article-title":"Identification and characterization of essential genes in the human genome","volume":"350","author":"Wang","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.coviro.2022.101270_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-07901-8","article-title":"Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities","volume":"9","author":"Sanson","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2022.101270_bib31","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.cell.2015.11.015","article-title":"High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities","volume":"163","author":"Hart","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2022.101270_sbref32","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2022.101270_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13805-y","article-title":"Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets","volume":"10","author":"Dempster","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2022.101270_sbref34","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-05506-9","article-title":"Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma","volume":"9","author":"Manzano","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2022.101270_sbref35","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01457-20","article-title":"Kaposi's Sarcoma-associated herpesvirus drives a super-enhancer-mediated survival gene expression program in primary effusion lymphoma","volume":"11","author":"Manzano","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.coviro.2022.101270_bib36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12967-022-03400-z","article-title":"CDK4\/6 inhibitors sensitize gammaherpesvirus-infected tumor cells to T-cell killing by enhancing expression of immune surface molecules","volume":"20","author":"Wu","year":"2022","journal-title":"J Transl Med"},{"key":"10.1016\/j.coviro.2022.101270_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-04916-6","article-title":"Inhibition of MCL1 induces apoptosis in anaplastic large cell lymphoma and in primary effusion lymphoma","volume":"12","author":"Quentmeier","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2022.101270_bib38","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1182\/blood-2006-06-028092","article-title":"Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling","volume":"109","author":"Sin","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101270_bib39","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1158\/1078-0432.CCR-04-1857","article-title":"Inhibition of phosphatidylinositol 3\u2032-kinase\/AKT signaling promotes apoptosis of primary effusion lymphoma cells","volume":"11","author":"Uddin","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coviro.2022.101270_bib40","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/onc.2015.245","article-title":"Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors","volume":"35","author":"Gopalakrishnan","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.coviro.2022.101270_bib41","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1038\/onc.2013.242","article-title":"Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors","volume":"33","author":"Tolani","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.coviro.2022.101270_bib42","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/d41573-020-00130-z","article-title":"p53 programmes plough on","volume":"19","author":"Mullard","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.coviro.2022.101270_bib43","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1172\/JCI83936","article-title":"Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies","volume":"127","author":"Nayar","year":"2017","journal-title":"J Clin Investig"},{"key":"10.1016\/j.coviro.2022.101270_bib44","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41564-018-0285-5","article-title":"Centrosomal protein TRIM43 restricts herpesvirus infection by regulating nuclear lamina integrity","volume":"4","author":"Full","year":"2019","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.coviro.2022.101270_bib45","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3389\/fonc.2019.00713","article-title":"The global landscape of EBV-associated tumors","volume":"9","author":"Shannon-Lowe","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.coviro.2022.101270_sbref46","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.chom.2017.04.005","article-title":"CRISPR\/Cas9 screens reveal Epstein-Barr virus-transformed B cell host dependency factors","volume":"21","author":"Ma","year":"2017","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coviro.2022.101270_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.867478","article-title":"Current perspectives in human T-cell leukemia virus type 1 infection and its associated diseases","volume":"9","author":"Miura","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.coviro.2022.101270_bib48","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood-2016-09-692574","article-title":"Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1-infected T cells","volume":"129","author":"Watanabe","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101270_sbref49","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ccell.2018.06.014","article-title":"Targeting the HTLV-I-regulated BATF3\/IRF4 transcriptional network in adult T cell leukemia\/lymphoma","volume":"34","author":"Nakagawa","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.coviro.2022.101270_sbref50","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood.2021012734","article-title":"Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia\/lymphoma","volume":"139","author":"Ishio","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101270_bib51","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2022.101270_bib52","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","article-title":"Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma","volume":"21","author":"Yang","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.coviro.2022.101270_bib53","doi-asserted-by":"crossref","first-page":"7591","DOI":"10.1093\/nar\/gku451","article-title":"SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity","volume":"42","author":"Care","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.coviro.2022.101270_bib54","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/s41375-018-0045-9","article-title":"The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17\/ILC3 skewing of anaplastic large cell lymphoma","volume":"32","author":"Schleussner","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.coviro.2022.101270_bib55","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/ni1357","article-title":"Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination","volume":"7","author":"Klein","year":"2006","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coviro.2022.101270_bib56","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.immuni.2006.07.009","article-title":"Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation","volume":"25","author":"Sciammas","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.coviro.2022.101270_bib57","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nrc.2016.62","article-title":"The role of enhancers in cancer","volume":"16","author":"Sur","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.coviro.2022.101270_sbref58","doi-asserted-by":"crossref","first-page":"21618","DOI":"10.1073\/pnas.1922216117","article-title":"Global epigenomic analysis of KSHV-infected primary effusion lymphoma identifies functional MYC superenhancers and enhancer RNAs","volume":"117","author":"Park","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2022.101270_sbref59","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20136-w","article-title":"Primary effusion lymphoma enhancer connectome links super-enhancers to dependency factors","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2022.101270_bib60","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.chom.2017.09.001","article-title":"The Epstein-Barr virus regulome in lymphoblastoid cells","volume":"22","author":"Jiang","year":"2017","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coviro.2022.101270_bib61","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1073\/pnas.1422580112","article-title":"Epstein-Barr virus nuclear antigen 3A partially coincides with EBNA3C genome-wide and is tethered to DNA through BATF complexes","volume":"112","author":"Schmidt","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2022.101270_bib62","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1073\/pnas.1321704111","article-title":"Epstein-Barr virus nuclear antigen 3C binds to BATF\/IRF4 or SPI1\/IRF4 composite sites and recruits Sin3A to repress CDKN2A","volume":"111","author":"Jiang","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2022.101270_bib63","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.chom.2014.12.013","article-title":"Epstein-Barr virus oncoprotein super-enhancers control B cell growth","volume":"17","author":"Zhou","year":"2015","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coviro.2022.101270_bib64","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.coviro.2022.101270_bib65","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.coviro.2022.101270_bib66","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood-2017-09-808063","article-title":"Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma","volume":"131","author":"Jin","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101270_bib67","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers","volume":"153","author":"Loven","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2022.101270_bib68","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/bloodadvances.2020003431","article-title":"Deciphering the mechanisms of CC-122 resistance in DLBCL via a genome-wide CRISPR screen","volume":"5","author":"Mo","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.coviro.2022.101270_bib69","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS","volume":"523","author":"Kronke","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2022.101270_bib70","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood-2018-01-828418","article-title":"CK1alpha and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma","volume":"132","author":"Patil","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.coviro.2022.101270_bib71","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2019031732","article-title":"Genome-wide CRISPR screens reveal genetic mediators of cereblon modulator toxicity in primary effusion lymphoma","volume":"3","author":"Patil","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.coviro.2022.101270_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009091","article-title":"Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2","volume":"17","author":"Shrestha","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2022.101270_bib73","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00866-19","article-title":"CRISPR-Cas9 screening of Kaposi's Sarcoma-associated herpesvirus-transformed cells identifies XPO1 as a vulnerable target of cancer cells","volume":"10","author":"Gruffaz","year":"2019","journal-title":"mBio"},{"key":"10.1016\/j.coviro.2022.101270_bib74","doi-asserted-by":"crossref","first-page":"28384","DOI":"10.1073\/pnas.2011645117","article-title":"screen identifies mitochondrial translation as an essential process in latent KSHV infection of human endothelial cells","volume":"117","author":"Holmes","year":"2020","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625722000815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625722000815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:03:34Z","timestamp":1778832214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625722000815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":74,"alternative-id":["S1879625722000815"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2022.101270","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Druggable host\u00a0gene dependencies in primary\u00a0effusion lymphoma","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2022.101270","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101270"}}